GWPH GW Pharmaceuticals Plc - Americ

106.13
-1.89  -2%
Previous Close 108.02
Open 107.97
Price To book 6.01
Market Cap 2.69B
Shares 25,308,000
Volume 219,092
Short Ratio 6.03
Av. Daily Volume 282,367

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released February 7, 2017. Abstract at ASCO June 5, 2017. Abstract 2046.
Tetrahydrocannabinol (THC) and cannabidiol (CBD)
Glioblastoma Multiform- cancer
Phase 2 trials to be initiated 1Q 2018.
GWP42006 (CBDV)
Rett syndrome
Phase 3 initiated December 2016.
Epidiolex
Infantile spasms (IS)
Phase 2 data released September 2015. Currently evaluating next steps
GWP42003
Schizophrenia
Phase 2 trial did not meet endpoint
GWP42004
Type 2 diabetes
Phase 3 trials failed. Evaluating whether there are any next steps
Sativex
Cancer pain
Phase 2 initiated May 2015. Data due 4Q 2017.
GWP42006 (CBDV)
Epilepsy
Second Phase 3 trial initiated mid April 2015. Data due 2017.
Epidiolex
Dravet Syndrome
Top line Phase 3 data released March 2016 met primary endpoint. NDA Filing due mid-2017.
Epidiolex
Dravet Syndrome
First Phase 3 trial data released June 2016. Data from second Phase 3 trial also met endpoint - September 2016. NDA filing due mid 2017.
Epidiolex
Lennox-Gastaut syndrome (LGS)
Phase 3 trial ongoing as of May 9, 2017.
Epidiolex
Tuberous Sclerosis Complex
Phase 2 trial did not meet primary endpoint - noted February 7, 2017.
Sativex
Spasticity due to cerebral palsy

Latest News

  1. Cannabis Industry Financial News Weekly Recap
  2. ETFs with exposure to GW Pharmaceuticals Plc : May 26, 2017
  3. Biotech Movers: Positive Phase Three Results For Roclatan Send Aerie Shares Soaring
  4. New England Journal of Medicine Publishes Cannabis Epilepsy Study
  5. Cannabis Drug Halved Convulsions in Company-Funded Epilepsy Test
  6. GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Publication of Groundbreaking Study of Epidiolex® (cannabidiol) in The New England Journal of Medicine
  7. 661 Million Reasons to Like These 3 Marijuana Stocks
  8. Blog Coverage: Bristol-Myers Squibs Received EMA Validation of Sprycel for the Treatment in Children with Chronic Myelogenous Leukemia
  9. Cannabis' Impact on the Brain in This New Study Should Encourage Marijuana Stock Investors
  10. The Truth About Investing in Marijuana Stocks
  11. Surprise! The Very First Marijuana Stock ETF Has Lost Investors Money
  12. GW Pharmaceuticals Announces Research & Development Management Appointments
  13. Is The Marijuana Stock Rally Over?
  14. GW Pharmaceuticals Plc :GWPH-US: Earnings Analysis: Q2, 2017 By the Numbers : May 12, 2017
  15. Analysts' Actions -- Chemours, Incyte, Visteon, Toyota and More
  16. Analyst: GW Pharma Has Started Laying The Groundwork For Taking Epidiolex To Market
  17. GW Pharmaceuticals plc Reports Fiscal Second Quarter 2017 Financial Results and Operational Progress
  18. Investor Network Invites You to the GW Pharmaceuticals Second Quarter 2017 Earnings Conference Call and Webcast Live on Tuesday, May 9, 2017
  19. 2 Compelling Reasons to Sell Marijuana Stocks – and 1 Reason Why You Shouldn’t